Mohamad A Kalot1, Abdallah El Alayli2,3, Mohammad Al Khatib4, Nedaa Husainat5, Kerri McGreal2, Diana I Jalal6, Alan S L Yu2,3, Reem A Mustafa2,3. 1. Department of Internal Medicine, State University of New York at Buffalo, Buffalo, New York. 2. Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas. 3. Division of Nephrology and Hypertension and the Jared Grantham Kidney Institute, Kansas City, Kansas. 4. Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar. 5. Department of Internal Medicine, St. Mary's Hospital, St. Louis, Missouri. 6. Department of Internal Medicine, University of Iowa Health Care, Iowa City, Iowa.
Abstract
Background: A computable phenotype is an algorithm used to identify a group of patients within an electronic medical record system. Developing a computable phenotype that can accurately identify patients with autosomal dominant polycystic kidney disease (ADPKD) will assist researchers in defining patients eligible to participate in clinical trials and other studies. Our objective was to assess the accuracy of a computable phenotype using International Classification of Diseases 9th and 10th revision (ICD-9/10) codes to identify patients with ADPKD. Methods: We reviewed four random samples of approximately 250 patients on the basis of ICD-9/10 codes from the EHR from the Kansas University Medical Center database: patients followed in nephrology clinics who had ICD-9/10 codes for ADPKD (Neph+), patients seen in nephrology clinics without ICD codes for ADPKD (Neph-), patients who were not followed in nephrology clinics with ICD codes for ADPKD (No Neph+), and patients not seen in nephrology clinics without ICD codes for ADPKD (No Neph-). We reviewed the charts and determined ADPKD status on the basis of internationally accepted diagnostic criteria for ADPKD. Results: The computable phenotype to identify patients with ADPKD who attended nephrology clinics has a sensitivity of 99% (95% confidence interval [95% CI], 96.4 to 99.7) and a specificity of 84% (95% CI, 79.5 to 88.1). For those who did not attend nephrology clinics, the sensitivity was 97% (95% CI, 93.3 to 99.0), and a specificity was 82% (95% CI, 77.4 to 86.1). Conclusion: A computable phenotype using the ICD-9/10 codes can correctly identify most patients with ADPKD, and can be utilized by researchers to screen health care records for cohorts of patients with ADPKD with acceptable accuracy.
Background: A computable phenotype is an algorithm used to identify a group of patients within an electronic medical record system. Developing a computable phenotype that can accurately identify patients with autosomal dominant polycystic kidney disease (ADPKD) will assist researchers in defining patients eligible to participate in clinical trials and other studies. Our objective was to assess the accuracy of a computable phenotype using International Classification of Diseases 9th and 10th revision (ICD-9/10) codes to identify patients with ADPKD. Methods: We reviewed four random samples of approximately 250 patients on the basis of ICD-9/10 codes from the EHR from the Kansas University Medical Center database: patients followed in nephrology clinics who had ICD-9/10 codes for ADPKD (Neph+), patients seen in nephrology clinics without ICD codes for ADPKD (Neph-), patients who were not followed in nephrology clinics with ICD codes for ADPKD (No Neph+), and patients not seen in nephrology clinics without ICD codes for ADPKD (No Neph-). We reviewed the charts and determined ADPKD status on the basis of internationally accepted diagnostic criteria for ADPKD. Results: The computable phenotype to identify patients with ADPKD who attended nephrology clinics has a sensitivity of 99% (95% confidence interval [95% CI], 96.4 to 99.7) and a specificity of 84% (95% CI, 79.5 to 88.1). For those who did not attend nephrology clinics, the sensitivity was 97% (95% CI, 93.3 to 99.0), and a specificity was 82% (95% CI, 77.4 to 86.1). Conclusion: A computable phenotype using the ICD-9/10 codes can correctly identify most patients with ADPKD, and can be utilized by researchers to screen health care records for cohorts of patients with ADPKD with acceptable accuracy.
Authors: Rachel L Richesson; W Ed Hammond; Meredith Nahm; Douglas Wixted; Gregory E Simon; Jennifer G Robinson; Alan E Bauck; Denise Cifelli; Michelle M Smerek; John Dickerson; Reesa L Laws; Rosemary A Madigan; Shelley A Rusincovitch; Cynthia Kluchar; Robert M Califf Journal: J Am Med Inform Assoc Date: 2013-08-16 Impact factor: 4.497
Authors: Hude Quan; Bing Li; L Duncan Saunders; Gerry A Parsons; Carolyn I Nilsson; Arif Alibhai; William A Ghali Journal: Health Serv Res Date: 2008-08 Impact factor: 3.402
Authors: Shawn N Murphy; Griffin Weber; Michael Mendis; Vivian Gainer; Henry C Chueh; Susanne Churchill; Isaac Kohane Journal: J Am Med Inform Assoc Date: 2010 Mar-Apr Impact factor: 4.497
Authors: Jérémie F Cohen; Daniël A Korevaar; Douglas G Altman; David E Bruns; Constantine A Gatsonis; Lotty Hooft; Les Irwig; Deborah Levine; Johannes B Reitsma; Henrica C W de Vet; Patrick M M Bossuyt Journal: BMJ Open Date: 2016-11-14 Impact factor: 2.692